Efforts are ongoing in developing anti-CD38 mAb (e.g., isatuximab) in combination with immunotherapy (e.g., cemiplimab, a programmed cell death protein 1 (PD-1) inhibitor) for NKTCL (NCT04763616) since CD38 has been shown to attenuate immune response to immune checkpoint therapy [17]. Here, PDCD1 is linked to extranodal nasal NK/T cell lymphoma.